Roche's (OTCQX:RHHBY)
plans to leverage Tecentriq as its next cancer blockbuster and offset
steep looming biosimilar sales erosion have been looking shakier and
shakier as the company continues to post okay-but-great data from
multiple trials, while chief rival Merck (MRK)
continues to post strong Keytruda data. While two recent positive trial
read-outs on Tecentriq in lung cancer and breast cancer are certainly
welcome, they're not likely going to change the tide of sentiment, and
management has work to do to convince the Street it's not an also-ran in
the making.
Click here for more:
Roche Reports Positive Clinical Results, But The Market Is Unimpressed
No comments:
Post a Comment